Small Pharma Inc., a clinical stage neuropharmaceutical company, engages in the IP-led development of novel treatments for depression and other mental health conditions. The company's lead product candidate is SPL026, a N,N-dimethyltryptamine (DMT) assisted therapy that is in Phase I/IIa randomized controlled clinical trial for the treatment of major depressive disorders. Its preclinical product candidates include SPL028 and SPL029 tryptamine analogues to assess and deliver alternative treatment profiles for the treatment of depression and other mental health disorders. The company was founded in 2015 and is headquartered in London, United Kingdom.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.18    OTCQB
As of 01/14/2022     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Index country:  United Kingdom
Country of incorporation:  
IPO date:  12/23/2021
Outstanding shares:  317,800,487
Average volume:  96,121
Market cap:   $60,922,353
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   -49.34
PB ratio:   1.13
PS ratio:   0.00
Return on equity:   -22.16%
Net income %:   -33,323.94%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy